Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effects of Baclofen on Presynaptic Inhibition in Humans
NCT04471714 · University of Alberta · PHASE2 · withdrawn · last registry update 2024-09-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study recruitment was halted due to restrictions and we have decided to not pursue it further.” | – | Registry record, University of Alberta |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GABBR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-07-14Phase 3 first posted: Adnan Imtiaj Rahul, Baclofen 10mg + Placebo (NCT07063576)
- 2025-05-11Phase 3 first posted: St. Joseph's Healthcare Hamilton, Multiprofen-CC™ plus standard treatment (NCT06966206)
- 2025-04-04Results posted on the registry: Kristina Simonyan, Sodium Oxybate (NCT03292458)
- 2024-11-18Results posted on the registry: Imperial College London, Baclofen + Vitamin D3 (NCT05161351)
- 2024-09-05Results posted on the registry: University of Alabama at Birmingham, Baclofen 10mg (NCT03720717)
- 2024-09-05Also stopped (terminated): University of Alabama at Birmingham, Baclofen 10mg (NCT03720717)
- 2024-07-29Phase 3 first posted: Avadel, FT218 (NCT06525077)
- 2024-01-12Phase 3 first posted: KAZM Pharmaceuticals Inc., Multiprofen-CC™ plus standard treatment (NCT06202989)
- 2024-01-09Results posted on the registry: Jazz Pharmaceuticals, JZP-258 (NCT04794491)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision